• What’s A Cure Worth? ICER Publishes Value Assessment Framework For Curative Therapies

    The Institute for Clinical and Economic Review (ICER) recently conducted a study of value assessment methods considered for “cures” or “potential cures” and solicited input from international HTA bodies. The research will form the basis of a value framework that will be applied in the assessment of potential cures and other treatments that qualify as what ICER refers to as “single or short-term transformative therapies.”

  • Brexit: The Good, The Bad, And The Chaos

    With just over half a year to go until the divorce date, and roughly two months until European Chief Brexit Negotiator Michel Barnier’s self-imposed October deadline for a Brexit deal, it has started to feel like we are finally seeing some concrete progress when it comes to Brexit.

  • Unpacking The Latest Brexit Developments And Their Potential Impact On Pharma

    As the divorce date approaches for the U.K. and the EU, one would be forgiven for thinking there would be a plan in place to deal with an event that will have such a profound global impact on the pharma industry. However, manufacturers have to prepare for any possibly scenario, while continuing to wait for clarity.

  • Should Pharma Companies Even Care About Brexit?

    It is difficult to assess the ultimate impact of Brexit on the pharmaceutical industry when so much remains unknown. However, many would argue it is exactly this uncertainty that makes Brexit so disruptive. 

  • What Is Pharmaceutical Innovation, Anyway? Italy’s New Algorithm & The Global Trend

    Innovation has long been a topic of focus in the pharmaceutical industry, with developers striving for it, regulators and payers demanding it. But, what exactly do we mean when we talk about “innovation”?

  • Brexit & The Biopharma Industry: 3 Important Developments To Watch

    There have been considerable updates in the Brexit situation since April 2017, including, the surprising result of the U.K. general election. If anything, news regarding Brexit and the biopharma industry has started to heat up in recent months, and there have been a number of relevant developments that manufacturers must keep their eye on.


Yulia Privolnev

Yulia Privolnev is a manager on the Global Market Access Insights team at Decision Resources Group (DRG). She is responsible for monitoring, analyzing, and reporting on global market access through the production of DRG’s Global Market Access Solution (GMAS) and Access & Reimbursement (A&R) products. Privolnev's specific focus is on all aspects of market access in Western and Eastern Europe, as well as international reference pricing (IRP) and managed entry agreements (MEAs) on a global scale. She earned her M.A. from the London School of Economics.